Simple Blood Test Enzyme Predicts Liver Cancer Survival

Predicting how a patient will respond to cancer therapy is a central challenge in oncology. For those with hepatocellular carcinoma (HCC), a common type of liver cancer, a new study suggests a simple blood marker could provide crucial foresight.

A meta-analysis, which statistically combines the results of ten previous studies involving 3,274 patients, investigated the role of an enzyme called gamma-glutamyltransferase (GGT). All patients were undergoing a treatment known as transarterial chemoembolization (TACE).

The pooled results showed a significant relationship: patients with elevated GGT levels before starting treatment had poorer overall survival rates. The analysis also found that high GGT was associated with other risk factors, including being male, having multiple tumours, and a poorer classification of liver function.

These findings indicate that measuring pre-treatment GGT can serve as a useful and accessible marker for predicting clinical outcomes in HCC patients, helping clinicians to better understand a patient's prognosis.